These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 21078939)

  • 1. Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates.
    van Hal SJ; Paterson DL
    Antimicrob Agents Chemother; 2011 Jan; 55(1):405-10. PubMed ID: 21078939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High vancomycin minimum inhibitory concentrations with heteroresistant vancomycin-intermediate Staphylococcus aureus in meticillin-resistant S. aureus bacteraemia patients.
    Wang JL; Lai CH; Lin HH; Chen WF; Shih YC; Hung CH
    Int J Antimicrob Agents; 2013 Nov; 42(5):390-4. PubMed ID: 24041465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcomes and molecular typing of heterogenous vancomycin-intermediate Staphylococcus aureus bacteremia in patients in intensive care units.
    Hu HC; Kao KC; Chiu LC; Chang CH; Hung CY; Li LF; Liu TP; Lin LC; Chen NH; Huang CC; Yang CT; Lu JJ
    BMC Infect Dis; 2015 Oct; 15():444. PubMed ID: 26497595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The incidence and risk factors for heterogeneous vancomycin intermediate Staphylococcus aureus].
    Feng NN; Wang Q; Song YL; He LX; Zhou CM; Xie HM; Li HY
    Zhonghua Nei Ke Za Zhi; 2013 Apr; 52(4):318-22. PubMed ID: 23925360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical implications of vancomycin heteroresistant and intermediately susceptible Staphylococcus aureus.
    Gomes DM; Ward KE; LaPlante KL
    Pharmacotherapy; 2015 Apr; 35(4):424-32. PubMed ID: 25884530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative proteomics-based identification of genes associated with glycopeptide resistance in clinically derived heterogeneous vancomycin-intermediate Staphylococcus aureus strains.
    Chen H; Liu Y; Zhao C; Xiao D; Zhang J; Zhang F; Chen M; Wang H
    PLoS One; 2013; 8(6):e66880. PubMed ID: 23840544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and clinical prognosis of heteroresistant vancomycin-intermediate Staphylococcus aureus in a tertiary care center in China.
    Wang Y; Hu YJ; Ai XM; Xu HT; Sun TY
    Chin Med J (Engl); 2013 Feb; 126(3):505-9. PubMed ID: 23422115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pneumonia Caused by Methicillin-Resistant Staphylococcus aureus: Does Vancomycin Heteroresistance Matter?
    Claeys KC; Lagnf AM; Hallesy JA; Compton MT; Gravelin AL; Davis SL; Rybak MJ
    Antimicrob Agents Chemother; 2016 Jan; 60(3):1708-16. PubMed ID: 26729497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of Staphylococcus aureus isolates with heterogeneous intermediate-level resistance to vancomycin in the United States.
    Richter SS; Satola SW; Crispell EK; Heilmann KP; Dohrn CL; Riahi F; Costello AJ; Diekema DJ; Doern GV
    J Clin Microbiol; 2011 Dec; 49(12):4203-7. PubMed ID: 21976769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterogeneous vancomycin resistance in Staphylococcus aureus: a review of epidemiology, diagnosis, and clinical significance.
    Rong SL; Leonard SN
    Ann Pharmacother; 2010 May; 44(5):844-50. PubMed ID: 20332341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between day 1 and day 2 Vancomycin area under the curve values and emergence of heterogeneous Vancomycin-intermediate Staphylococcus aureus (hVISA) by Etest® macromethod among patients with MRSA bloodstream infections: a pilot study.
    Martirosov DM; Bidell MR; Pai MP; Scheetz MH; Rosenkranz SL; Faragon C; Malik M; Mendes RE; Jones RN; McNutt LA; Lodise TP
    BMC Infect Dis; 2017 Aug; 17(1):534. PubMed ID: 28764660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular epidemiology and clinical characteristics of hetero-resistant vancomycin intermediate Staphylococcus aureus bacteremia in a Taiwan Medical Center.
    Lin SY; Chen TC; Chen FJ; Chen YH; Lin YI; Siu LK; Lu PL
    J Microbiol Immunol Infect; 2012 Dec; 45(6):435-41. PubMed ID: 22749725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications.
    Howden BP; Davies JK; Johnson PD; Stinear TP; Grayson ML
    Clin Microbiol Rev; 2010 Jan; 23(1):99-139. PubMed ID: 20065327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA) emerged before the clinical introduction of vancomycin in Japan: a retrospective study.
    Yamakawa J; Aminaka M; Okuzumi K; Kobayashi H; Katayama Y; Kondo S; Nakamura A; Oguri T; Hori S; Cui L; Ito T; Jin J; Kurosawa H; Kaneko K; Hiramatsu K
    J Infect Chemother; 2012 Jun; 18(3):406-9. PubMed ID: 22033576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterogeneous vancomycin resistance in Staphylococcus aureus does not predict development of vancomycin resistance upon vancomycin pressure.
    Gaillard T; Dupieux-Chabert C; Butin M; Dumitrescu O; Naceur O; Bouveyron C; Martra A; Bes M; Tristan A; Vandenesch F; Lina G; Laurent F; Rasigade JP
    J Antimicrob Chemother; 2022 Mar; 77(4):1032-1035. PubMed ID: 35022718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic effect of vancomycin combined with cefotaxime, imipenem, or meropenem against Staphylococcus aureus with reduced susceptibility to vancomycin.
    Srisrattakarn A; Chaiyapoke C; Booncharoen S; Wongthong S; Chanawong A; Tippayawat P; Tavichakorntrakool R; Lulitanond A
    Turk J Med Sci; 2021 Aug; 51(4):2150-2158. PubMed ID: 33705643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure.
    Kelley PG; Gao W; Ward PB; Howden BP
    J Antimicrob Chemother; 2011 May; 66(5):1057-60. PubMed ID: 21393156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High prevalence of a globally disseminated hypervirulent clone, Staphylococcus aureus CC121, with reduced vancomycin susceptibility in community settings in China.
    Shen P; Zhou K; Wang Y; Song J; Liu Y; Zhou Y; Xiao Y
    J Antimicrob Chemother; 2019 Sep; 74(9):2537-2543. PubMed ID: 31203362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and microbiologic analysis of the risk factors for mortality in patients with heterogeneous vancomycin-intermediate Staphylococcus aureus bacteremia.
    Chong YP; Park KH; Kim ES; Kim MN; Kim SH; Lee SO; Choi SH; Jeong JY; Woo JH; Kim YS
    Antimicrob Agents Chemother; 2015; 59(6):3541-7. PubMed ID: 25845875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA among methicillin-resistant S. aureus with high vancomycin minimal inhibitory concentrations in Taiwan: A multicenter surveillance study, 2012-2013.
    Huang SH; Chen YC; Chuang YC; Chiu SK; Fung CP; Lu PL; Wang LS; Wu TL; Wang JT
    J Microbiol Immunol Infect; 2016 Oct; 49(5):701-707. PubMed ID: 26320398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.